^
    BIOMARKER:

    TP53 wild-type

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Entrez ID:
    7157
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    TP53 wild-type
    Myelodysplastic Syndrome
    GS-4721
    Sensitive
    :
    C3
    SOHO 2022 - 5 days - (New C3)
    TP53 wild-type
    Solid Tumor
    BI 907828
    Sensitive
    :
    C2
    ESMO 2022 - 3 weeks - (New C3)
    TP53 wild-type
    Small Lymphocytic Lymphoma
    PCR
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    FCR
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    alemtuzumab
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    rituximab
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    chlorambucil
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    venetoclax + obinutuzumab
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    CD20 inhibitor
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    rituximab + idelalisib
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    obinutuzumab + acalabrutinib
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    ibrutinib + obinutuzumab
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    zanubrutinib
    Sensitive
    :
    A2
    TP53 wild-type
    Small Lymphocytic Lymphoma
    rituximab + ibrutinib
    Sensitive
    :
    A2
    TP53 wild-type
    Chronic Lymphocytic Leukemia
    zanubrutinib
    Sensitive
    :
    A2
    TP53 wild-type
    Chronic Lymphocytic Leukemia
    venetoclax
    Sensitive
    :
    A2
    TP53 wild-type
    Acute Myelogenous Leukemia
    RO5503781
    Resistant
    :
    B
    TP53 wild-type
    Endometrial Cancer
    selinexor
    Sensitive
    :
    B
    TP53 wild-type
    Lymphoma
    ALRN-6924
    Sensitive
    :
    C2
    TP53 wild-type
    Solid Tumor
    ALRN-6924
    Sensitive
    :
    C2
    TP53 wild-type
    Solid Tumor
    KRT-232
    Sensitive
    :
    C2
    TP53 wild-type
    Estrogen Receptor Positive Breast Cancer
    ALRN-6924
    Sensitive
    :
    C2
    TP53 wild-type
    Acute Myelogenous Leukemia
    HDM201
    Sensitive
    :
    C3
    TP53 wild-type
    Solid Tumor
    HDM201
    Sensitive
    :
    C3
    TP53 wild-type
    Liposarcoma
    MK-8242
    Sensitive
    :
    C3
    TP53 wild-type
    Solid Tumor
    MK-8242
    Sensitive
    :
    C3
    TP53 wild-type
    Multiple Myeloma
    KRT-232
    Sensitive
    :
    C3
    TP53 wild-type
    Liposarcoma
    HDM201
    Sensitive
    :
    C3
    TP53 wild-type
    Merkel Cell Carcinoma
    KRT-232
    Sensitive
    :
    C3
    TP53 wild-type
    Melanoma
    trametinib + dabrafenib + KRT-232
    Sensitive
    :
    C3
    TP53 wild-type
    Acute Myelogenous Leukemia
    venetoclax
    Sensitive
    :
    C3
    TP53 wild-type
    Breast Cancer
    selinexor + chidamide
    Sensitive
    :
    D
    TP53 wild-type
    Breast Cancer
    chidamide
    Sensitive
    :
    D
    TP53 wild-type
    Acute Myelogenous Leukemia
    thioureidobutyronitrile
    Sensitive
    :
    D